166 related articles for article (PubMed ID: 30094492)
1. Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women.
Areán-Cuns C; Mercado-Gutiérrez M; Paniello-Alastruey I; Mallor-Giménez F; Córdoba-Iturriagagoitia A; Lozano-Escario M; Santamaria-Martínez M
Virchows Arch; 2018 Nov; 473(5):599-606. PubMed ID: 30094492
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of p16/Ki67 immunostaining in the triage of women referred to colposcopy.
Ordi J; Sagasta A; Munmany M; Rodríguez-Carunchio L; Torné A; del Pino M
Cancer Cytopathol; 2014 Mar; 122(3):227-35. PubMed ID: 24757722
[TBL] [Abstract][Full Text] [Related]
3. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
[TBL] [Abstract][Full Text] [Related]
4. p16/Ki67 dual staining improves the detection specificity of high-grade cervical lesions.
Zhang R; Ge X; You K; Guo Y; Guo H; Wang Y; Geng L
J Obstet Gynaecol Res; 2018 Nov; 44(11):2077-2084. PubMed ID: 30094887
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG
Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
[TBL] [Abstract][Full Text] [Related]
6. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
[TBL] [Abstract][Full Text] [Related]
7. A population of 1136 HPV DNA-HR positive women: expression of p16(INK4a)/Ki67 Dual-Stain Cytology and cytological diagnosis. Histological correlations and cytological follow up.
Rossi P; Borghi L; Ferro R; Mencarelli R
Pathologica; 2015; 107(3-4):185-91. PubMed ID: 26946874
[TBL] [Abstract][Full Text] [Related]
8. Performance of P16/Ki67 dual staining in triaging hr-HPV-positive population during cervical Cancer screening in the younger women.
Qian QP; Zhang X; Ding B; Jiang SW; Li ZM; Ren ML; Shen Y
Clin Chim Acta; 2018 Aug; 483():281-285. PubMed ID: 29758205
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
[TBL] [Abstract][Full Text] [Related]
10. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
[TBL] [Abstract][Full Text] [Related]
11. Importance of addition of HPV DNA testing to the cytology based cervical cancer screening and triage of findings with p16/Ki67 immunocytochemistry staining in 35 and 45 years old women LIBUSE trial data analysis.
Sláma J; Dvořák V; Trnková M; Skřivánek A; Hurdálková K; Ovesná P; Nováčková M
Ceska Gynekol; 2020; 85(6):368-374. PubMed ID: 33711896
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
14. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of p16/Ki-67 dual-stain as triage test for high-risk HPV-positive women: A hospital-based cross-sectional study.
Chen X; Chen C; Liu L; Dai W; Zhang J; Han C; Zhou S
Cancer Cytopathol; 2022 Dec; 130(12):955-963. PubMed ID: 35852302
[TBL] [Abstract][Full Text] [Related]
16. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of different triage strategies for human papillomavirus positivity in an Italian screening population.
Gustinucci D; Benevolo M; Cesarini E; Mancuso P; Passamonti B; Giaimo MD; Corvetti R; Nofrini V; Bulletti S; Malaspina M; Tintori B; Giorgi Rossi P;
Int J Cancer; 2022 Mar; 150(6):952-960. PubMed ID: 34706093
[TBL] [Abstract][Full Text] [Related]
18. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.
Zhu Y; Ren C; Yang L; Zhang X; Liu L; Wang Z
BMC Cancer; 2019 Mar; 19(1):271. PubMed ID: 30917784
[TBL] [Abstract][Full Text] [Related]
19. Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
Luttmer R; De Strooper LM; Steenbergen RD; Berkhof J; Snijders PJ; Heideman DA; Meijer CJ
Expert Rev Mol Diagn; 2016 Sep; 16(9):961-74. PubMed ID: 27459506
[TBL] [Abstract][Full Text] [Related]
20. Should we use risk selection tests for HPV 16 and/or 18 positive cases: Comparison of p16/Ki67 and cytology.
Mazurec K; Trzeszcz M; Mazurec M; Streb J; Halon A; Jach R
J Med Virol; 2024 Mar; 96(3):e29500. PubMed ID: 38440951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
